2021
DOI: 10.1016/j.jddst.2020.102155
|View full text |Cite
|
Sign up to set email alerts
|

5-Fluorouracil, innovative drug delivery systems to enhance bioavailability for topical use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
25
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 28 publications
(30 citation statements)
references
References 72 publications
0
25
0
Order By: Relevance
“…Thus, a high dose needs to be administered to reach effective intracellular concentrations. It has a narrow therapeutic index with a high incidence of side effects ( Ewert de Oliveira et al, 2021 ). Some of the most common are mucositis, diarrhea, or myelosuppression.…”
Section: Peripheral Neuropathy: Neuropathic Painmentioning
confidence: 99%
“…Thus, a high dose needs to be administered to reach effective intracellular concentrations. It has a narrow therapeutic index with a high incidence of side effects ( Ewert de Oliveira et al, 2021 ). Some of the most common are mucositis, diarrhea, or myelosuppression.…”
Section: Peripheral Neuropathy: Neuropathic Painmentioning
confidence: 99%
“…As a broad‐spectrum anti‐tumor anthracycline, doxorubicin (DOX) has been being widely used to treat various cancers, such as thyroid, stomach, lung, and bone cancers 3 . And 5‐fluorouracil (5‐FU) as a pyrimidine derivative with broad‐spectrum antitumor activity, has also been widely applied in cancer chemotherapy 28 . The combination of DOX and 5‐FU in multi‐target therapy has shown superior antitumor activity to either one alone, indicating their synergistic inhibitory effect on tumor growth 29,30 .…”
Section: Introductionmentioning
confidence: 99%
“…3 And 5-fluorouracil (5-FU) as a pyrimidine derivative with broad-spectrum antitumor activity, has also been widely applied in cancer chemotherapy. 28 The combination of DOX and 5-FU in multi-target therapy has shown superior antitumor activity to either one alone, indicating their synergistic inhibitory effect on tumor growth. 29,30 As we know, DOX is hydrophobic and 5-FU is hydrophilic, so encapsulating the both into the different parts of the core-shell PNIPAM@GO microspheres is so appropriate to get a multi-target platform.…”
Section: Introductionmentioning
confidence: 99%
“…Likewise, a 2009 publication by Corporate Safety, Health & Environmental Protection, Switzerland, reported a figure of 1545 kg of 5-FU per year excreted into wastewater in Europe [17]. The use of carriers (nanoparticles and vesicles) that facilitate an efficient delivery system for this drug helps to improve this situation [18][19][20], although the definitive solution to the problem is still far from being obtained.…”
Section: Introductionmentioning
confidence: 99%
“…Likewise, the use of liposomes as carriers/encapsulating agents of 5-FU has been extensively studied [30][31][32] to both improve its bioavailability and reduce side effects, as compared to traditional formulations used under the form of creams and/or emulsions [33][34][35], for topical use in the treatment of different skin diseases [19,36]. Lakkakula et al [20] found that 5-FU could be encapsulated in the cavity of 2HP-β-cyclodextrin, forming a stable inclusion complex, although they did not report the extent of such complex formation.…”
Section: Introductionmentioning
confidence: 99%